Healthcare -
Biotechnology - NASDAQ - US
$ 2.0
-4.76 %
$ 175 M
Market Cap
-1.79
P/E
1. INTRINSIC VALUE
Balance Sheet
Terns Pharmaceuticals, Inc.
| Current Assets | 362 M |
| Cash & Short-Term Investments | 358 M |
| Receivables | 0 |
| Other Current Assets | 3.94 M |
| Non-Current Assets | 1.82 M |
| Long-Term Investments | 0 |
| PP&E | 1.47 M |
| Other Non-Current Assets | 350 K |
| Current Liabilities | 15.6 M |
| Accounts Payable | 2.15 M |
| Short-Term Debt | 428 K |
| Other Current Liabilities | 13.1 M |
| Non-Current Liabilities | 2.41 M |
| Long-Term Debt | 919 K |
| Other Non-Current Liabilities | 1.49 M |
EFFICIENCY
Earnings Waterfall
Terns Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 102 M |
| Operating Income | -102 M |
| Other Expenses | -13 M |
| Net Income | -88.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Terns Pharmaceuticals, Inc.
| Net Income | -88.9 M |
| Depreciation & Amortization | 896 K |
| Capital Expenditures | -42 K |
| Stock-Based Compensation | 15.6 M |
| Change in Working Capital | 4.38 M |
| Others | 2.66 M |
| Free Cash Flow | -70.1 M |
Wall Street Analysts Price Targets
Terns Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for TERN of $18.7 , with forecasts ranging from
a
low of
$10 to a high of $26 .
TERN Lowest Price Target
Wall Street Target
10 USD
400.00%
TERN Average Price Target
Wall Street Target
18.7 USD
833.33%
TERN Highest Price Target
Wall Street Target
26 USD
1200.00%
4. DIVIDEND
ANALYSIS
TERN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Terns Pharmaceuticals, Inc.
Sold
0-3 MONTHS
2.37 K USD 1
3-6 MONTHS
211 K USD 3
6-9 MONTHS
1.67 M USD 4
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
125 K USD 2
3-6 MONTHS
5 M USD 1
6-9 MONTHS
42.5 K USD 2
9-12 MONTHS
7. News
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
- 6 days ago
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals (TERN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 1 week ago
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns.
globenewswire.com
- 1 week ago
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 2 weeks ago
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 FOSTER CITY, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided corporate updates.
globenewswire.com
- 3 weeks ago
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss company boasts even more significant upside potential, judging by Wall Street's predictions: Terns Pharmaceuticals (TERN -3.86%).
fool.com
- 1 month ago
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 24, 2025 an equity inducement award to Andrew Gengos, the Company's new chief financial officer, under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity award was approved by the Compensation Committee of the Company's Board of Directors and the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to Mr. Gengos' acceptance of employment with Terns.
globenewswire.com
- 1 month ago
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25
globenewswire.com
- 1 month ago
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Seasoned public company CFO with 25 years of leadership experience in biotech Seasoned public company CFO with 25 years of leadership experience in biotech
globenewswire.com
- 1 month ago
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise
globenewswire.com
- 1 month ago
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:00 p.m. ET.
globenewswire.com
- 2 months ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns.
globenewswire.com
- 2 months ago
8. Profile
Summary
Terns Pharmaceuticals, Inc. TERN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 175 M
Dividend Yield
0.00%
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Contact
1065 East Hillsdale Boulevard, Foster City, CA, 94404
https://www.ternspharma.com
IPO
Date
Feb. 5, 2021
Employees
59
Officers
Ms. Amy L. Burroughs M.B.A.
Chief Executive Officer & Director
Mr. Andrew W. Gengos
Chief Financial Officer
Ms. Elona Kogan Esq., J.D.
Chief Legal Officer
Dr. Jeffrey R. Jasper Ph.D.
Senior Vice President of Research
Dr. Emil T. Kuriakose M.D.
Chief Medical Officer
Ms. Melita Sun Jung
Chief Business Officer
Mr. Scott Harris
Chief Development Officer
Ms. Debra Sieminski
Senior Vice President of Medical Affairs
Mr. James Kanter
Senior Vice President of CMC
Mr. David Eric Strauss
Vice President of Finance & Controller